Hümmelink R, Sippell W G
Pädiatrische Endokrinologie, Universitäts-Kinderklinik Kiel.
Monatsschr Kinderheilkd. 1988 Sep;136(9):618-21.
Many stimulation tests are available for the assessment of growth hormone release from the pituitary in clinical practice. Three of the most common tests are insulin-hypoglycaemia, arginine stimulation and spontaneous hGH nocturnal peaks and profiles. In this study we compared the Growth hormone releasing-hormone (GHRH)-test in a dose of 1 microgram/kg b.w. with these three other tests for evaluation of the somatotropic function of the pituitary. Each of these four tests was performed in 29 children with short stature due to growth failure of various etiologies and height-deficits (-SDS) of -3.0 +/- 0.5 SE. The peak plasma hGH levels of all patients after GHRH stimulation did not correlate with the respective peak values during insulin (r = 0.02) and arginine (r = 0.28) stimulation and with peak levels during the spontaneous nocturnal hGH profile (r = 0.18). The diagnostic value of the GHRH test alone is thus still questionable in establishing the diagnosis of a hypothalamic GHRH/GH defect, because some of these patients do not react to the first GHRH dose as one might expect, but only after a few days of repeated injections of GHRH (priming). The tolerance of intravenous injections of GHRH was excellent. The mean plasma GH response to GHRH was higher (p less than 0.05) in the group of children with constitutional short stature than in GH deficient patients, but there were overlaps in this group with normal volunteers and other groups of patients with growth failure.
在临床实践中,有许多刺激试验可用于评估垂体生长激素的释放。最常见的三种试验是胰岛素低血糖试验、精氨酸刺激试验以及生长激素夜间自发峰值和曲线测定。在本研究中,我们将剂量为1微克/千克体重的生长激素释放激素(GHRH)试验与其他三种试验进行比较,以评估垂体的生长激素功能。这四种试验分别在29名因各种病因生长发育迟缓且身高标准差评分(-SDS)为-3.0±0.5的身材矮小儿童中进行。所有患者经GHRH刺激后的血浆生长激素峰值水平与胰岛素刺激(r = 0.02)、精氨酸刺激(r = 0.28)时的相应峰值以及夜间生长激素自发曲线的峰值水平均无相关性(r = 0.18)。因此,仅靠GHRH试验在诊断下丘脑GHRH/生长激素缺陷方面的诊断价值仍值得怀疑,因为其中一些患者对首次GHRH剂量的反应并不像预期的那样,而是在重复注射GHRH(启动)几天后才出现反应。静脉注射GHRH的耐受性良好。体质性身材矮小儿童组对GHRH的平均血浆生长激素反应高于生长激素缺乏患者(p < 0.05),但该组与正常志愿者以及其他生长发育迟缓患者组存在重叠。